Oncology

Luis E. Raez, MD, incoming president of the Florida Society of Clinical Oncology, provides an overview of his goals for his upcoming term.

In a panel discussion during the Business of Oncology Summit hosted by the Florida Society of Clinical Oncology, survivors and caregivers described how their cancer journeys were affected by financial toxicity.

"By being a part of this membership, you get access to education, information, resources, [and] materials that are hopefully going to be helpful in the care of cancer patients," said Rick McDonough, MD, president of the Florida Society of Clinical Oncology (FLASCO).

In a disucssion about closing the rural cancer care gap, 3 themes emerged: local efforts, clinical trial access, and telehealth.

Community oncology practices need to come together as much as possible in order to respond to changes in the market, have a common voice, and to share best practices and learn from each other, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.

The care team is made up of a number of members, who work together to uncover and then address any barriers that patients have, said Jessa Dunivan, patient services manager, Northwest Medical Specialties.

As clinicians learn how to manage patients most efficiently under a value-based care of delivery, they need to identify patients and risk-stratify those patients, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.

Targeted interventions by patient characteristics to improve fecal immunochemical test completion could reduce disparities in colorectal cancer screening and improve overall compliance with screening recommendations.

Alexandra Quinn, chief executive officer, Health Leads, discusses the growing role of community health workers in cancer care and why it's important to make the work they do more sustainable.

Oncology needs to learn to use technology not just for keeping medical records, but also for caring for patients, explained Erich Mounce, chief operating officer, OneOncology.

Genetic alternations in colorectal cancer (CRC) are linked to different survival and treatment outcomes, according to a study that used next-generation sequencing (NGS) of tumor DNA. The study was published in Journal of Clinical Oncology.

Early intervention to identify social needs means issues get caught sooner and patients can avoid or minimize financial toxicity, said Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.

The first day of the 2019 Community Oncology Conference, the major annual meeting of the Community Oncology Alliance (COA), featured an update on its effort to find alternatives to CMS' Oncology Care Model.

There's still a big disparity in reimbursement between hospitals and community-based practices, but is looking into ways to address this, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.

The Patient Access Network (PAN) Foundation today opened a new patient assistance program for people living with Waldenstrom macroglobulinemia, a rare type of blood cancer that originates in the lymphatic system and is characterized by an excess of abnormal white blood cells and proteins called immunoglobulins.

Today we’re speaking with Dr Elizabeth Mynatt, the executive director of the Institute for People and Technology and a professor in the College of Computing at the Georgia Institute of Technology. Dr Mynatt and her team developed an app called MyPath that uses artificial intelligence to help guide a patient’s cancer journey.

As novel therapies drive up the cost of drugs, it is becoming increasingly difficult for community oncologists to keep costs below value-based care program targets, according to a new survey from Integra Connect.

The revolution in cancer care isn’t just about the wave of life-saving therapies, or the role of genetics in pinpointing exactly who should get which drug and when. As Ray D. Page, DO, PhD, FACOI, tells it, change also means getting back to the basics, so that the relationship between doctor and patient drives care—not insurance companies or Medicare or rules from the FDA.

Tom Gallo, the former president of the Association of Community Cancer Centers (ACCC), and Ali McBride, PharmD, the current president of ACCC, discuss how their members feel about the state of cancer delivery, recent trends, addressing burnout, and sustainability of cancer care delivery.

A lack of diversity in cell lines used for laboratory studies means underrepresented populations and minorities might not benefit from precision medicines as quickly as people from European ancestry.

Ali McBride, PharmD, MS, BCOP, was named 2019-2020 president of the Association of Community Cancer Centers (ACCC) during its 45th Annual Meeting & Cancer Center Business Summit on March 22, 2019, in Washington, DC. McBride is the clinical coordinator of hematology/oncology at The University of Arizona Cancer Center.

Everyone at the practice is vital to the success of value-based care, which is really patient-centered care, said Jessa Dunivan, patient services manager, Northwest Medical Specialties.

At the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center and president of ACCC, discussed the role of biosimilars in oncology and how familiar oncologists and their teams are with them.

Biomarker testing will start to evolve to look more at combination therapies, said Jarushka Naidoo, MB BCh, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

The move to value-based care has increased the use of palliative care, and new research has found that conversations about end-of-life care should be happening earlier, said Toby C. Campbell, MD, MSCI, of the University of Wisconsin Carbone Cancer Center.

There are a lot of different ways for identifying patients that might have barriers to care or might be considered as high-risk, says Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.

Although there is still a need for more education around the use of biosimilars in cancer, it seems oncologists have become more knowledgeable in the past few years, said Gary H. Lyman, MD, MPH, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Erich Mounce, chief operating officer, OneOncology, drew on his experience from West Cancer Center to discuss how community oncology can improve access to care and other inequalities in cancer care.

This week, the FDA sent out an alert to various healthcare professionals and the public to warn about the risks associated with the investigational use of venetoclax (Venclexta) for the treatment of patients with multiple myeloma (MM). The alert is based on data from the ongoing phase 3 BELLINI trial evaluating the drug for this treatment.